Biocon’s arm to acquire Viatris’ Biosimilars Assets for up to $3.33 billion
Biopharmaceutical company Biocon on Monday announced that the board of directors of Biocon Biologics Limited, a material subsidiary of Biocon Limited, has approved the proposed acquisition of biosimilars assets of Viatris Inc. The transaction is subject to necessary regulatory and other approvals. Viatris will receive consideration of up to $3.335 billion, including cash up to … Read more